Vanda Pharmaceuticals Gains Rare FDA Hearing for HETLIOZ® Treatment of Jet Lag Disorder

Vanda Pharmaceuticals Secures Rare FDA Hearing for HETLIOZ® on Jet Lag Disorder

Vanda Pharmaceuticals Inc. faces a significant regulatory milestone as the U.S. Food and Drug Administration (FDA) grants the company a formal evidentiary public hearing regarding its supplemental new drug application (sNDA) for HETLIOZ® (tasimelteon), aimed at treating jet lag disorder. This rare decision, communicated in a letter from the Office of the Commissioner on March 2, 2026, indicates a deviation from the FDA's typical regulatory process where such public hearings have not been conducted for over four decades. The hearing represents a critical step for Vanda as it seeks to expand HETLIOZ®'s utility beyond its current indications, which include Non-24-Hour Sleep-Wake Disorder and sleep disturbances related to Smith-Magenis syndrome.

Vanda’s President and CEO, Mihael H. Polymeropoulos, expresses optimism over this procedural development. He cites the company’s dedicated efforts over the past seven years to advocate for scientific integrity and the need for fair treatment when exploring innovative therapeutic options. HETLIOZ® addresses a pressing public health issue, targeting jet lag, a condition that affects millions of travelers globally and currently has no FDA-approved treatment. Polymeropoulos’s remarks emphasize the importance of providing solutions for significant unmet medical needs, positioning Vanda at the forefront of developing treatments that can alleviate jet lag's disruptive effects on daily life.

The FDA’s decision to hold a hearing is particularly noteworthy given the backdrop of Vanda’s previous legal victory against the FDA. The U.S. Court of Appeals for the D.C. Circuit ruled that the FDA had unlawfully dismissed Vanda's clinical evidence supporting the drug’s effectiveness. As the pending hearing proceeds under the regulations set forth by 21 CFR Part 12, a presiding officer will evaluate the evidence presented and issue an initial decision according to section 12.120. This pivotal moment underscores not only the company's resilience but also its commitment to advance therapeutic options for conditions that have historically been neglected in regulatory discussions.

In light of this hearing, Vanda Pharmaceuticals is poised to reinforce its mission of addressing critical health challenges through innovative solutions. The outcome of this evidentiary hearing could have far-reaching implications for both the company's future and the evolving landscape of treatments for jet lag disorder.

As Vanda navigates this regulatory process, the firm remains focused on its broader goal of developing therapies that meet the healthcare needs of underserved populations, exemplifying its commitment to enhancing patient outcomes in a rapidly changing pharmaceutical landscape.